fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

State of the art clinical trials

Written by | 6 May 2019

Professor Sagar Lonial (Atlanta, USA) opened the UKMF by discussing the latest evidence in the management of myeloma, with comment from session chair Professor Gordon Cook (Leeds, UK).

Frontline therapy in multiple myeloma therapy: current evidence and future research

Written by | 2 May 2019

Professor Graham Jackson (Newcastle, UK) held a ‘meet the expert’ session at BSH 2019 covering the rapidly changing world of frontline therapy in myeloma.

Highlights from BSH 2019

Written by | 1 May 2019

The 2019 annual meeting of the BSH showcased the best UK research with over 36 sessions covering a range of important issues related to the treatment of haematological… read more.

BSH 2018: Hodgkin lymphoma: tackling treatment challenges in the older patient

Written by | 21 Jun 2018

Managing Hodgkin lymphoma in elderly patients can be challenging, given that trial data do not reflect the picture in elderly patients and performance status can vary widely. The… read more.

BSH 2018: Molecular biology to drive rational drug usage

Written by | 20 Jun 2018

Gene expression profiling has shown that that the activated B-cell and germinal centre B-cell subtypes of diffuse large B-cell lymphoma are driven by different oncogenic pathways and this may… read more.

BSH 2018 Highlights

Written by | 20 Jun 2018

In the video, Dr Cathy Burton (Leeds), Dr Stella Bowcock (London) and Dr Stephen Robinson (Bristol) give their highlights from this year’s BSH meeting, including the Lymphoma Specialist Interest Group (SIG) which held a… read more.

BSH 2018: Creating off-site, nurse-led treatment units for administration of chemotherapy to people with lymphoma

Written by | 20 Jun 2018

The launch of biosimilar rituximab provided an opportunity to save £300,000 per year but called for time-consuming intravenous administration that exceeded the capacity of the hospital unit. Off-site… read more.

BSH 2018: Debate: CAR-T cell therapy will become the standard of care for relapsed high-grade B-cell lymphoma within 5 years

Written by | 11 May 2018

Is CAR-T cell therapy a realistic treatment option for patients with large B cell lymphoma who otherwise have no curative options or an expensive new treatment that is… read more.

BSH 2018: Access to new agents

Written by | 11 May 2018

Cancer drugs receive special funding in the NHS but it is not automatic and input from expert clinicians is essential to ensure that effective treatments are funded appropriately…. read more.

BSH 2018: Personalised cancer vaccines and cellular therapy: changing the treatment paradigm for haematological malignancies

Written by | 11 May 2018

Dendritic cells (DC) are known to play an important role in the initiation of primary immune responses. In cancer, deficient DCs contribute to tumour-associated immune tolerance. Functionally active… read more.

BSH 2018: Stratified medicine – using genomic analysis to deliver therapy in high-risk myeloma

Written by | 11 May 2018

Dr Martin Kaiser (London) discusses recent work from the UK on identifying robust markers and how clinical decisions can be made according to the biology of the disease. Advances… read more.

BSH 2017: Management of Asymptomatic Follicular Lymphoma

Written by | 24 Apr 2017

The old mantra is that advanced follicular lymphoma (FL) cannot be cured and treatment does not influence survival but this is no longer the case – follicular lymphoma… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.